IMCR

SEC source: 0001955244-25-000005 · form4-09162025_040906.xml · nonDerivative · entry 2

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,300

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.22 to $36.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001955244-25-000005 · form4-09162025_040906.xml · nonDerivative · entry 1

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,532

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.

SEC source: 0001415889-25-024359 · form4-09122025_040901.xml · derivative · entry 7

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 221,371

Underlying: Ordinary Shares · 19,081 shares

Expires 2028-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.

F5 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-024359 · form4-09122025_040901.xml · nonDerivative · entry 5

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.91 to $36.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-024359 · form4-09122025_040901.xml · nonDerivative · entry 4

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,081

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.

SEC source: 0001415889-25-024359 · form4-09122025_040901.xml · derivative · entry 6

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 240,452

Underlying: Ordinary Shares · 31,338 shares

Expires 2028-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.

F5 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-024359 · form4-09122025_040901.xml · nonDerivative · entry 3

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.66 to $36.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-024359 · form4-09122025_040901.xml · nonDerivative · entry 2

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,200

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.66 to $36.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-024359 · form4-09122025_040901.xml · nonDerivative · entry 1

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,338

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.

SEC source: 0000950170-25-074307 · ownership.xml · derivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 26,198

Underlying: Ordinary Shares · 26,198 shares

Expires 2035-05-14

F1 · shares: Includes 26,198 non-qualified share options ("Share Options") exercisable solely into ordinary shares ("Ordinary shares") of Immunocore Holdings plc (the "Issuer") granted by the Issuer to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on May 15, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2021 Equity Incentive Plan (the "Incentive Plan"). The Share Options have a strike price of $29.06 per share, and vest on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of shareholders of the Issuer, subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board") through the vesting date. The Share Options expire on May 14, 2035.

F1 · derivative.exercise_date: Includes 26,198 non-qualified share options ("Share Options") exercisable solely into ordinary shares ("Ordinary shares") of Immunocore Holdings plc (the "Issuer") granted by the Issuer to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on May 15, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2021 Equity Incentive Plan (the "Incentive Plan"). The Share Options have a strike price of $29.06 per share, and vest on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of shareholders of the Issuer, subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board") through the vesting date. The Share Options expire on May 14, 2035.

F1 · derivative.expiration_date: Includes 26,198 non-qualified share options ("Share Options") exercisable solely into ordinary shares ("Ordinary shares") of Immunocore Holdings plc (the "Issuer") granted by the Issuer to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on May 15, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2021 Equity Incentive Plan (the "Incentive Plan"). The Share Options have a strike price of $29.06 per share, and vest on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of shareholders of the Issuer, subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board") through the vesting date. The Share Options expire on May 14, 2035.

F1 · derivative.underlying_shares: Includes 26,198 non-qualified share options ("Share Options") exercisable solely into ordinary shares ("Ordinary shares") of Immunocore Holdings plc (the "Issuer") granted by the Issuer to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on May 15, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2021 Equity Incentive Plan (the "Incentive Plan"). The Share Options have a strike price of $29.06 per share, and vest on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of shareholders of the Issuer, subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board") through the vesting date. The Share Options expire on May 14, 2035.

F1 · balance_after: Includes 26,198 non-qualified share options ("Share Options") exercisable solely into ordinary shares ("Ordinary shares") of Immunocore Holdings plc (the "Issuer") granted by the Issuer to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on May 15, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2021 Equity Incentive Plan (the "Incentive Plan"). The Share Options have a strike price of $29.06 per share, and vest on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of shareholders of the Issuer, subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board") through the vesting date. The Share Options expire on May 14, 2035.

F2 · ownership.nature: Ranjeev Krishana serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: The acquisition of Share Options reported on this form represents a single grant to Ranjeev Krishana of 26,198 Share Options on Table II. This grant of 26,198 Share Options for Ranjeev Krishana is reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F7 · ownership.nature: Pursuant to the policies of the Adviser, Ranjeev Krishana does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary shares, Share Options and Ordinary shares issued upon exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F8 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options and any Ordinary shares received as a result of the exercise of Share Options.

F9 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Share Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-074307 · ownership.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 26,198

Underlying: Ordinary Shares · 26,198 shares

Expires 2035-05-14

F1 · shares: Includes 26,198 non-qualified share options ("Share Options") exercisable solely into ordinary shares ("Ordinary shares") of Immunocore Holdings plc (the "Issuer") granted by the Issuer to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on May 15, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2021 Equity Incentive Plan (the "Incentive Plan"). The Share Options have a strike price of $29.06 per share, and vest on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of shareholders of the Issuer, subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board") through the vesting date. The Share Options expire on May 14, 2035.

F1 · derivative.exercise_date: Includes 26,198 non-qualified share options ("Share Options") exercisable solely into ordinary shares ("Ordinary shares") of Immunocore Holdings plc (the "Issuer") granted by the Issuer to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on May 15, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2021 Equity Incentive Plan (the "Incentive Plan"). The Share Options have a strike price of $29.06 per share, and vest on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of shareholders of the Issuer, subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board") through the vesting date. The Share Options expire on May 14, 2035.

F1 · derivative.expiration_date: Includes 26,198 non-qualified share options ("Share Options") exercisable solely into ordinary shares ("Ordinary shares") of Immunocore Holdings plc (the "Issuer") granted by the Issuer to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on May 15, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2021 Equity Incentive Plan (the "Incentive Plan"). The Share Options have a strike price of $29.06 per share, and vest on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of shareholders of the Issuer, subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board") through the vesting date. The Share Options expire on May 14, 2035.

F1 · derivative.underlying_shares: Includes 26,198 non-qualified share options ("Share Options") exercisable solely into ordinary shares ("Ordinary shares") of Immunocore Holdings plc (the "Issuer") granted by the Issuer to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on May 15, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2021 Equity Incentive Plan (the "Incentive Plan"). The Share Options have a strike price of $29.06 per share, and vest on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of shareholders of the Issuer, subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board") through the vesting date. The Share Options expire on May 14, 2035.

F1 · balance_after: Includes 26,198 non-qualified share options ("Share Options") exercisable solely into ordinary shares ("Ordinary shares") of Immunocore Holdings plc (the "Issuer") granted by the Issuer to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on May 15, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2021 Equity Incentive Plan (the "Incentive Plan"). The Share Options have a strike price of $29.06 per share, and vest on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of shareholders of the Issuer, subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board") through the vesting date. The Share Options expire on May 14, 2035.

F2 · ownership.nature: Ranjeev Krishana serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Share Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F6 · ownership.nature: The acquisition of Share Options reported on this form represents a single grant to Ranjeev Krishana of 26,198 Share Options on Table II. This grant of 26,198 Share Options for Ranjeev Krishana is reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F7 · ownership.nature: Pursuant to the policies of the Adviser, Ranjeev Krishana does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary shares, Share Options and Ordinary shares issued upon exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F8 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options and any Ordinary shares received as a result of the exercise of Share Options.

SEC source: 0001415889-25-013627 · form4-05192025_040514.xml · derivative · entry 1

Ratcliffe Peter John · CIK 0001969518 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,198

Underlying: Ordinary Shares · 26,198 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) May 15, 2026 and (ii) the day immediately prior to the date of our next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-013626 · form4-05192025_040512.xml · derivative · entry 1

Pao William · CIK 0001919343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,198

Underlying: Ordinary Shares · 26,198 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) May 15, 2026 and (ii) the day immediately prior to the date of our next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-013625 · form4-05192025_040510.xml · derivative · entry 1

Herbst Roy Steven · CIK 0001969520 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,198

Underlying: Ordinary Shares · 26,198 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) May 15, 2026 and (ii) the day immediately prior to the date of our next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-013624 · form4-05192025_040508.xml · derivative · entry 1

Peterson Kristine · CIK 0001508596 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,198

Underlying: Ordinary Shares · 26,198 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) May 15, 2026 and (ii) the day immediately prior to the date of our next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-013622 · form4-05192025_040504.xml · derivative · entry 1

Bell John Irving · CIK 0001969932 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,198

Underlying: Ordinary Shares · 26,198 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) May 15, 2026 and (ii) the day immediately prior to the date of our next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-013623 · form4-05192025_040506.xml · derivative · entry 1

Kaul Siddharth · CIK 0001969522 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,198

Underlying: Ordinary Shares · 26,198 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) May 15, 2026 and (ii) the day immediately prior to the date of our next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0000950170-25-042242 · ownership.xml · derivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: American Depositary Shares · 1,449,226 shares

Expires 2030-02-01

F7 · security: These securities consist of 2.5% Convertible Senior Notes due 2030 of the Issuer ("2.5% Convertible Notes") that accrue interest at a rate of 2.50% per annum, payable semi-annually in arrears on February 1 and August 1 of each year, beginning on August 1, 2024 and mature on February 1, 2030. The 2.5% Convertible Notes are convertible at any time at a conversion rate of 10.5601 ADS for each $1,000 of principal amount of the 2.5% Convertible Note without payment or further consideration, subject to a 4.99% beneficial ownership limitation described below.

F8 · security: The 2.5% Convertible Notes are only convertible to the extent that as a result of such conversion the holders thereof together with their affiliates and any persons who are members of a Section 13(d) group with the holders or their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding Ordinary Shares after conversion (the "2.5% Convertible Notes Beneficial Ownership Limitation"). By written notice to the Issuer, the Funds may from time to time increase or decrease the 2.5% Convertible Notes Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer.

F7 · derivative.exercise_price: These securities consist of 2.5% Convertible Senior Notes due 2030 of the Issuer ("2.5% Convertible Notes") that accrue interest at a rate of 2.50% per annum, payable semi-annually in arrears on February 1 and August 1 of each year, beginning on August 1, 2024 and mature on February 1, 2030. The 2.5% Convertible Notes are convertible at any time at a conversion rate of 10.5601 ADS for each $1,000 of principal amount of the 2.5% Convertible Note without payment or further consideration, subject to a 4.99% beneficial ownership limitation described below.

F9 · price: The sales price calculation for the 2.5% Convertible Notes was based on the volume weighted average price of the ADS in the market on March 17, 2025.

F7 · derivative.exercise_date: These securities consist of 2.5% Convertible Senior Notes due 2030 of the Issuer ("2.5% Convertible Notes") that accrue interest at a rate of 2.50% per annum, payable semi-annually in arrears on February 1 and August 1 of each year, beginning on August 1, 2024 and mature on February 1, 2030. The 2.5% Convertible Notes are convertible at any time at a conversion rate of 10.5601 ADS for each $1,000 of principal amount of the 2.5% Convertible Note without payment or further consideration, subject to a 4.99% beneficial ownership limitation described below.

F8 · derivative.exercise_date: The 2.5% Convertible Notes are only convertible to the extent that as a result of such conversion the holders thereof together with their affiliates and any persons who are members of a Section 13(d) group with the holders or their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding Ordinary Shares after conversion (the "2.5% Convertible Notes Beneficial Ownership Limitation"). By written notice to the Issuer, the Funds may from time to time increase or decrease the 2.5% Convertible Notes Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer.

F7 · derivative.underlying_shares: These securities consist of 2.5% Convertible Senior Notes due 2030 of the Issuer ("2.5% Convertible Notes") that accrue interest at a rate of 2.50% per annum, payable semi-annually in arrears on February 1 and August 1 of each year, beginning on August 1, 2024 and mature on February 1, 2030. The 2.5% Convertible Notes are convertible at any time at a conversion rate of 10.5601 ADS for each $1,000 of principal amount of the 2.5% Convertible Note without payment or further consideration, subject to a 4.99% beneficial ownership limitation described below.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F11 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may have been deemed to have an indirect pecuniary interest in the securities reported as disposed in column 5 of Table II that were directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-042242 · ownership.xml · derivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: American Depositary Shares · 134,789 shares

Expires 2030-02-01

F7 · security: These securities consist of 2.5% Convertible Senior Notes due 2030 of the Issuer ("2.5% Convertible Notes") that accrue interest at a rate of 2.50% per annum, payable semi-annually in arrears on February 1 and August 1 of each year, beginning on August 1, 2024 and mature on February 1, 2030. The 2.5% Convertible Notes are convertible at any time at a conversion rate of 10.5601 ADS for each $1,000 of principal amount of the 2.5% Convertible Note without payment or further consideration, subject to a 4.99% beneficial ownership limitation described below.

F8 · security: The 2.5% Convertible Notes are only convertible to the extent that as a result of such conversion the holders thereof together with their affiliates and any persons who are members of a Section 13(d) group with the holders or their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding Ordinary Shares after conversion (the "2.5% Convertible Notes Beneficial Ownership Limitation"). By written notice to the Issuer, the Funds may from time to time increase or decrease the 2.5% Convertible Notes Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer.

F7 · derivative.exercise_price: These securities consist of 2.5% Convertible Senior Notes due 2030 of the Issuer ("2.5% Convertible Notes") that accrue interest at a rate of 2.50% per annum, payable semi-annually in arrears on February 1 and August 1 of each year, beginning on August 1, 2024 and mature on February 1, 2030. The 2.5% Convertible Notes are convertible at any time at a conversion rate of 10.5601 ADS for each $1,000 of principal amount of the 2.5% Convertible Note without payment or further consideration, subject to a 4.99% beneficial ownership limitation described below.

F9 · price: The sales price calculation for the 2.5% Convertible Notes was based on the volume weighted average price of the ADS in the market on March 17, 2025.

F7 · derivative.exercise_date: These securities consist of 2.5% Convertible Senior Notes due 2030 of the Issuer ("2.5% Convertible Notes") that accrue interest at a rate of 2.50% per annum, payable semi-annually in arrears on February 1 and August 1 of each year, beginning on August 1, 2024 and mature on February 1, 2030. The 2.5% Convertible Notes are convertible at any time at a conversion rate of 10.5601 ADS for each $1,000 of principal amount of the 2.5% Convertible Note without payment or further consideration, subject to a 4.99% beneficial ownership limitation described below.

F8 · derivative.exercise_date: The 2.5% Convertible Notes are only convertible to the extent that as a result of such conversion the holders thereof together with their affiliates and any persons who are members of a Section 13(d) group with the holders or their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding Ordinary Shares after conversion (the "2.5% Convertible Notes Beneficial Ownership Limitation"). By written notice to the Issuer, the Funds may from time to time increase or decrease the 2.5% Convertible Notes Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer.

F7 · derivative.underlying_shares: These securities consist of 2.5% Convertible Senior Notes due 2030 of the Issuer ("2.5% Convertible Notes") that accrue interest at a rate of 2.50% per annum, payable semi-annually in arrears on February 1 and August 1 of each year, beginning on August 1, 2024 and mature on February 1, 2030. The 2.5% Convertible Notes are convertible at any time at a conversion rate of 10.5601 ADS for each $1,000 of principal amount of the 2.5% Convertible Note without payment or further consideration, subject to a 4.99% beneficial ownership limitation described below.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may have been deemed to have had an indirect pecuniary interest in the securities reported as disposed in column 5 of Table II that were directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

SEC source: 0000950170-25-042242 · ownership.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,144,060

F1 · security: American Depositary Shares ("ADS") of Immunocore Holdings plc (the "Issuer"), each representing one Ordinary Share ("Ordinary Shares") of the Issuer.

F6 · price: The price reported in Column 4 is a weighted average price. These ADS were traded by the Funds in multiple transactions at prices ranging from $29.01 to $30.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-042242 · ownership.xml · nonDerivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 178,596

F1 · security: American Depositary Shares ("ADS") of Immunocore Holdings plc (the "Issuer"), each representing one Ordinary Share ("Ordinary Shares") of the Issuer.

F6 · price: The price reported in Column 4 is a weighted average price. These ADS were traded by the Funds in multiple transactions at prices ranging from $29.01 to $30.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0000950170-25-042242 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,051,711

F1 · security: American Depositary Shares ("ADS") of Immunocore Holdings plc (the "Issuer"), each representing one Ordinary Share ("Ordinary Shares") of the Issuer.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-042242 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 170,007

F1 · security: American Depositary Shares ("ADS") of Immunocore Holdings plc (the "Issuer"), each representing one Ordinary Share ("Ordinary Shares") of the Issuer.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001415889-25-005857 · form4-02272025_090204.xml · derivative · entry 1

Pao William · CIK 0001919343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,443

Underlying: Ordinary Shares · 24,443 shares

Expires 2035-02-24

F1 · derivative.exercise_date: This option vests in equal monthly installments over a three-year period measured from one month following February 25, 2025, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001415889-25-004610 · form4-02192025_090230.xml · derivative · entry 2

St Leger Tina Amber · CIK 0001969525 · CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,476

Underlying: Ordinary Shares · 8,476 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share.

F3 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.

F3 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001415889-25-004610 · form4-02192025_090230.xml · derivative · entry 1

St Leger Tina Amber · CIK 0001969525 · CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,212

Underlying: Ordinary Shares · 23,212 shares

Expires 2035-02-16

F1 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 17, 2026, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001415889-25-004607 · form4-02192025_090208.xml · derivative · entry 2

GOLL JOHN · CIK 0001779466 · SVP, FINANCE & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,405

Underlying: Ordinary Shares · 5,405 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share.

F3 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.

F3 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001415889-25-004607 · form4-02192025_090208.xml · derivative · entry 1

GOLL JOHN · CIK 0001779466 · SVP, FINANCE & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,802

Underlying: Ordinary Shares · 14,802 shares

Expires 2035-02-16

F1 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 17, 2026, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001415889-25-004605 · form4-02192025_090204.xml · derivative · entry 2

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,297

Underlying: Ordinary Shares · 47,297 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share.

F3 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.

F3 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001415889-25-004605 · form4-02192025_090204.xml · derivative · entry 1

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,518

Underlying: Ordinary Shares · 129,518 shares

Expires 2035-02-16

F1 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 17, 2026, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001415889-25-004602 · form4-02192025_090204.xml · derivative · entry 2

Jallal Bahija · CIK 0001730038 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,270

Underlying: Ordinary Shares · 95,270 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share.

F3 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.

F3 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001415889-25-004602 · form4-02192025_090204.xml · derivative · entry 1

Jallal Bahija · CIK 0001730038 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 405,824

Underlying: Ordinary Shares · 405,824 shares

Expires 2035-02-16

F1 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 17, 2026, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001415889-25-000390 · form4-01032025_090124.xml · derivative · entry 1

Coy Travis Alan · CIK 0001969524 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 274,033

Underlying: Ordinary Shares · 274,033 shares

Expires 2034-12-31

F1 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on January 1, 2026, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0000950170-24-066036 · ownership.xml · derivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,925

Underlying: Ordinary Shares · 12,925 shares

Expires 2035-05-27

F1 · shares: Includes 12,925 non-qualified options to purchase ordinary shares ("Share Options") of Immunocore Holdings plc (the "Issuer") granted to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser") pursuant to the Issuer's 2021 Equity Incentive Plan. The Share Options have a strike price of $46.05 and vest in equal monthly installments over three years subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board"). The Share Options expire on May 27, 2035. Ranjeev Krishana serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") and their affiliates and control persons.

F2 · shares: Pursuant to the policies of the Adviser, Ranjeev Krishana does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Share Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interests in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options (i.e. no direct pecuniary interest). Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options and any ordinary shares of the Issuer ("Ordinary Shares") acquired as a result of the exercise of the Share Options.

F1 · derivative.exercise_date: Includes 12,925 non-qualified options to purchase ordinary shares ("Share Options") of Immunocore Holdings plc (the "Issuer") granted to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser") pursuant to the Issuer's 2021 Equity Incentive Plan. The Share Options have a strike price of $46.05 and vest in equal monthly installments over three years subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board"). The Share Options expire on May 27, 2035. Ranjeev Krishana serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") and their affiliates and control persons.

F1 · derivative.expiration_date: Includes 12,925 non-qualified options to purchase ordinary shares ("Share Options") of Immunocore Holdings plc (the "Issuer") granted to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser") pursuant to the Issuer's 2021 Equity Incentive Plan. The Share Options have a strike price of $46.05 and vest in equal monthly installments over three years subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board"). The Share Options expire on May 27, 2035. Ranjeev Krishana serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") and their affiliates and control persons.

F1 · derivative.underlying_shares: Includes 12,925 non-qualified options to purchase ordinary shares ("Share Options") of Immunocore Holdings plc (the "Issuer") granted to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser") pursuant to the Issuer's 2021 Equity Incentive Plan. The Share Options have a strike price of $46.05 and vest in equal monthly installments over three years subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board"). The Share Options expire on May 27, 2035. Ranjeev Krishana serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") and their affiliates and control persons.

F2 · derivative.underlying_shares: Pursuant to the policies of the Adviser, Ranjeev Krishana does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Share Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interests in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options (i.e. no direct pecuniary interest). Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options and any ordinary shares of the Issuer ("Ordinary Shares") acquired as a result of the exercise of the Share Options.

F1 · balance_after: Includes 12,925 non-qualified options to purchase ordinary shares ("Share Options") of Immunocore Holdings plc (the "Issuer") granted to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser") pursuant to the Issuer's 2021 Equity Incentive Plan. The Share Options have a strike price of $46.05 and vest in equal monthly installments over three years subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board"). The Share Options expire on May 27, 2035. Ranjeev Krishana serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") and their affiliates and control persons.

F2 · balance_after: Pursuant to the policies of the Adviser, Ranjeev Krishana does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Share Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interests in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options (i.e. no direct pecuniary interest). Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options and any ordinary shares of the Issuer ("Ordinary Shares") acquired as a result of the exercise of the Share Options.

F2 · ownership.nature: Pursuant to the policies of the Adviser, Ranjeev Krishana does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Share Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interests in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options (i.e. no direct pecuniary interest). Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options and any ordinary shares of the Issuer ("Ordinary Shares") acquired as a result of the exercise of the Share Options.

F3 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: The acquisition of Share Options reported on this form represents a single grant to Ranjeev Krishana of 12,925 Share Options on Table II. This grant of 12,925 Share Options for Ranjeev Krishana is reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F7 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Share Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-066036 · ownership.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,925

Underlying: Ordinary Shares · 12,925 shares

Expires 2035-05-27

F1 · shares: Includes 12,925 non-qualified options to purchase ordinary shares ("Share Options") of Immunocore Holdings plc (the "Issuer") granted to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser") pursuant to the Issuer's 2021 Equity Incentive Plan. The Share Options have a strike price of $46.05 and vest in equal monthly installments over three years subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board"). The Share Options expire on May 27, 2035. Ranjeev Krishana serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") and their affiliates and control persons.

F2 · shares: Pursuant to the policies of the Adviser, Ranjeev Krishana does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Share Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interests in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options (i.e. no direct pecuniary interest). Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options and any ordinary shares of the Issuer ("Ordinary Shares") acquired as a result of the exercise of the Share Options.

F1 · derivative.exercise_date: Includes 12,925 non-qualified options to purchase ordinary shares ("Share Options") of Immunocore Holdings plc (the "Issuer") granted to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser") pursuant to the Issuer's 2021 Equity Incentive Plan. The Share Options have a strike price of $46.05 and vest in equal monthly installments over three years subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board"). The Share Options expire on May 27, 2035. Ranjeev Krishana serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") and their affiliates and control persons.

F1 · derivative.expiration_date: Includes 12,925 non-qualified options to purchase ordinary shares ("Share Options") of Immunocore Holdings plc (the "Issuer") granted to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser") pursuant to the Issuer's 2021 Equity Incentive Plan. The Share Options have a strike price of $46.05 and vest in equal monthly installments over three years subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board"). The Share Options expire on May 27, 2035. Ranjeev Krishana serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") and their affiliates and control persons.

F1 · derivative.underlying_shares: Includes 12,925 non-qualified options to purchase ordinary shares ("Share Options") of Immunocore Holdings plc (the "Issuer") granted to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser") pursuant to the Issuer's 2021 Equity Incentive Plan. The Share Options have a strike price of $46.05 and vest in equal monthly installments over three years subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board"). The Share Options expire on May 27, 2035. Ranjeev Krishana serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") and their affiliates and control persons.

F2 · derivative.underlying_shares: Pursuant to the policies of the Adviser, Ranjeev Krishana does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Share Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interests in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options (i.e. no direct pecuniary interest). Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options and any ordinary shares of the Issuer ("Ordinary Shares") acquired as a result of the exercise of the Share Options.

F1 · balance_after: Includes 12,925 non-qualified options to purchase ordinary shares ("Share Options") of Immunocore Holdings plc (the "Issuer") granted to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser") pursuant to the Issuer's 2021 Equity Incentive Plan. The Share Options have a strike price of $46.05 and vest in equal monthly installments over three years subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board"). The Share Options expire on May 27, 2035. Ranjeev Krishana serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") and their affiliates and control persons.

F2 · balance_after: Pursuant to the policies of the Adviser, Ranjeev Krishana does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Share Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interests in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options (i.e. no direct pecuniary interest). Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options and any ordinary shares of the Issuer ("Ordinary Shares") acquired as a result of the exercise of the Share Options.

F2 · ownership.nature: Pursuant to the policies of the Adviser, Ranjeev Krishana does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Share Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interests in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options (i.e. no direct pecuniary interest). Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options and any ordinary shares of the Issuer ("Ordinary Shares") acquired as a result of the exercise of the Share Options.

F3 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Share Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F6 · ownership.nature: The acquisition of Share Options reported on this form represents a single grant to Ranjeev Krishana of 12,925 Share Options on Table II. This grant of 12,925 Share Options for Ranjeev Krishana is reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0001415889-24-014657 · form4-05282024_040513.xml · derivative · entry 1

Kaul Siddharth · CIK 0001969522 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,534

Underlying: Ordinary Shares · 14,534 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) May 23, 2025 and (ii) the day immediately prior to the date of our next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-014656 · form4-05282024_040510.xml · derivative · entry 1

Ratcliffe Peter John · CIK 0001969518 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,534

Underlying: Ordinary Shares · 14,534 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) May 23, 2025 and (ii) the day immediately prior to the date of our next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-014655 · form4-05282024_040507.xml · derivative · entry 1

Peterson Kristine · CIK 0001508596 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,534

Underlying: Ordinary Shares · 14,534 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) May 23, 2025 and (ii) the day immediately prior to the date of our next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-014654 · form4-05282024_040504.xml · derivative · entry 1

Herbst Roy Steven · CIK 0001969520 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,534

Underlying: Ordinary Shares · 14,534 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) May 23, 2025 and (ii) the day immediately prior to the date of our next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-014653 · form4-05282024_040501.xml · derivative · entry 1

Bell John Irving · CIK 0001969932 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,534

Underlying: Ordinary Shares · 14,534 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) May 23, 2025 and (ii) the day immediately prior to the date of our next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-009989 · form4-04032024_040401.xml · derivative · entry 3

St Leger Tina Amber · CIK 0001969525 · CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Ordinary Shares · 4,375 shares

Expires 2032-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2023.

F3 · derivative.exercise_date: 25% of the shares subject to the option award vested on April 1, 2023, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001415889-24-009989 · form4-04032024_040401.xml · nonDerivative · entry 2

St Leger Tina Amber · CIK 0001969525 · CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.73 to $64.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-009989 · form4-04032024_040401.xml · nonDerivative · entry 1

St Leger Tina Amber · CIK 0001969525 · CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2023.

SEC source: 0001415889-24-006079 · form4-03012024_040305.xml · derivative · entry 6

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 271,790

Underlying: Ordinary Shares · 36,509 shares

Expires 2028-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023.

F6 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-24-006079 · form4-03012024_040305.xml · nonDerivative · entry 5

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.42 to $70.48 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-006079 · form4-03012024_040305.xml · nonDerivative · entry 4

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,200

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.26 to $70.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-006079 · form4-03012024_040305.xml · nonDerivative · entry 3

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,137

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.26 to $69.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-006079 · form4-03012024_040305.xml · nonDerivative · entry 2

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,609

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.08 to $68.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-006079 · form4-03012024_040305.xml · nonDerivative · entry 1

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,509

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023.

SEC source: 0001415889-24-005720 · form4-02282024_040201.xml · derivative · entry 10

Berman David M · CIK 0001955244 · HEAD OF R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 308,299

Underlying: Ordinary Shares · 54,938 shares

Expires 2028-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023.

F8 · derivative.exercise_date: Immediately exercisable.